| Original language | English (US) |
|---|---|
| Article number | e162962 |
| Journal | Journal of Clinical Investigation |
| Volume | 132 |
| Issue number | 16 |
| DOIs | |
| State | Published - Aug 15 2022 |
Funding
Support was provided by the Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Cancer Center and NIH grants NS120547 and CA120813. Conflict of interest: ABH serves on the advisory board of Caris Life Sciences and the WCG Oncology Advisory Board; receives royalty and milestone payments from DNAtrix for the licensing of “Biomarkers and combination therapies using oncolytic virus and immunomodulation” (patent 11,065,285); and is supported by research grants from Celu-larity, Codiak BioSciences, and AbbVie. She additionally has active granted patents for “miRNA for treating cancer and for use with adoptive immunotherapies” (patent 9,675,633) and “Concurrent chemotherapy and immunotherapy” (patent 9,399,662), with a patent pending for “Low intensity ultrasound combination cancer therapies” (International applications PCT/US2022/019435 and US 63/158,642). Copyright: © 2022, Heimberger et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License. Reference information: J Clin Invest. 2022;132(16):e162962. https://doi.org/10.1172/JCI162962.
ASJC Scopus subject areas
- General Medicine
